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Expression of surface antigens on cells compnsmg 
malignant, dysplastic, and benign pigment cell lesions 
has been evaluated in s itu us ing an avidin-biotin im-
munohistologic technique. We have demonstrated 
expression of HLA-DR, ,82 -microglobulin, and 2 mela-
noma-associated antigens (MAA) in a range of benign 
and malignant lesion, and have confirmed the close as-
sociation of HLA-DR and MAA on malignant lesions. In 
addition , 5 subcutaneous lesions removed at the same 
time from one individual were evaluated. Clinical and 
histologic appearance differed among lesions although 
the antige nic patte rns were similar. 
The ide nt ification of a prema ligna nt lesion o r state, and t he 
abili ty to predict t he likelihood of malign an t t ra nsformation o f 
t hat les ion o r t he deve lopment of a related ma lign a ncy e lse-
whe re in or on th e body m ay help in prevent ing cancer or 
detectin g it at a n early curable stage in t he popula tion at la rge. 
Furt hermore improved prognostic indices for t he proba bility of 
in vasion or metastasis may refin e our application of surgica l 
a nd adjuvant medical t herapy. It has been sh own t ha t the 
a nt igenic phe notype of a ma ligna nt lesion may predict so me of 
t he bio logic cha racte ristics of t hat lesion [1- 4]. Wit h t he advent 
of monoc lona l a nti bodies against class I a nd II a ntige ns of t he 
majo r hi s toco mpat ibili ty locus, and against tumor-associated 
a nt ige ns, we a re able to explore t he a ntige nic phenotyp e of 
no rma l, premalignan t , a nd maligna nt les ions. The dysplastic 
nevus has been ident ified as a precurser les ion of mela noma 
present in approx imately 40% of patients studied wit h a histo ry 
of mela noma [5,6]. W e have u nderta ken t he characterization 
of t he a nt igenic phenotype of nev i, dysplastic nevi , a nd mela-
noma, a nd report here our res ult s of an tibody studies in 89 
lesions. 
MATERIALS AND METHODS 
S ubject.s and S pecimens 
Patients were asked to part icipate in the investigation of pigment 
lesions and gave informed consent for each excisional biopsy (Yale IRB 
1/2802). Each specimen was divided fo r studies of routine pathology in 
paraffi n-embedded t issue and snap-frozen in OCT for studies of im -
munohisto logy. OCT -embedded (Ames Di vision of Miles Laboratories, 
E lkhart, Indiana) tissue was stored at -80' C. Twenty-two nonmalig-
nant pigment cell les ions from patients wi th a history of melanoma, 1 
primary melanoma, and 11 metastatic melanomas were biopsied from 
34 individuals. In addi tion, 1 patient (LM) had .5 subcutaneous meta-
static nodules removed for immunohisto logic evaluation, each one 
appea ring clinically different in its pi gmentation , ranging from black 
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PBS: phosphate-buffered saline 
to fl esh tone. Immunohistologic sections of these lesions were scored 
on a 1- 8 scale based on number of cells staining and intensity of sta in. 
Histopathology 
The diagnosis of each lesion was made by light microscopic exami -
nation of paraffin -embedded specimens stained with hematoxylin and 
eosin in t he Dermatopathology Laboratory of t he Yale- New Haven 
Hospital. Separately, the specimens were reviewed by two dermato-
pat hologists (P.D. and K.S.). Biopsy specimens of pigmented lesions 
were classified as normal nevocellular nevi, dysplastic nevi , primary 
melanoma, or metastat ic melanoma based on cri te ria of Elder and 
Clark [6,7]. 
Monoclonal Antibodies 
Ant ibody 96.5 against the p97 antigen was supplied by HybriTech 
(San Diego, California) , and against p250 from Biogenex (Dublin , 
California). Anti-{32-microglobulin and anti-OR were supplied by Bec-
ton Dickinson (Sunnyvale, California). In addit ion anti-SB and MT l 
were kindly provided by Dr. L. Nadler (Dana- Farber Cancer Institute, 
Boston, Massachusetts) . 
I rnmu.noh~~to logy 
Six to eight micron thick sections were cut on a Lipshaw microtome 
and placed on gelatin-coated slides. After air drying for 12 h, the 
specimen was fixed in acetone at 4' C for 10 min and hydrated in 
phosphate-buffered saline (PBS) at pH 7.4 . Sections were first incu-
bated with the appropriate antibody at a dilution of 1:100 or 1:1000 in 
PBS + 1% bovine serum albumin or in PBS and 1% bovine serum 
albumin alone fo r control for 60 min in humidified chambers at room 
temperature. Following 2 washes in PBS, sections were developed by 
the avidin -biotin technique using a Vectastain Kit (Vector, Burlingame, 
Ca lifornia). Briefly, biotinylated goat antimouse an tibody was allowed 
to react for '12 h with each section followed by 2 washes in PBS. Next 
avidin -biotin -peroxidase complexes were reacted with each section for 
1/2 h, washed 2 t imes as before, and developed with 3-amino-9-ethylca r-
bazole (Aldrich Chemical Co Inc, Milwaukee, Wisconsin) dissolved in 
dimethylformamide and diluted in acetate buffer (pH 5) and hydrogen 
peroxide. Sections were scored for staining of pigment cells in the lesion 
by one investigator (M.S.E.) who was blinded to the origin of t he 
specimen, and reviewed subsequently by all authors. 
RESULTS 
Seven tee n nevocellular nevi, 1 congenital nevus , 4 dysplastic 
nevi , 1 primary melanoma, and 11 metastatic melanomas we re 
eva luated (see T able I) . Of 17 nevocellula r nevi , 8 had expressed 
significant quantities of j)2-microglobulin, 5 expressed DR, 1 
expressed p97, a nd 5 expressed p 250. On the other hand, the 
majority of metastatic melanomas expressed all 4 antigens. 
Five subcuta neous metastases rem oved from a s ingle patien t 
revealed histomorphology t ha t was cons istent with the gross 
clinical appea rance; the heavily pigmented lesion was composed 
of dendritic a nd spindloid mela nocytes while the nonpigmen ted 
ones were composed prima rily of epi t helioid cells (see Fig 1, 2). 
Nevert he less a ll 5 h ad s imila r sta ining patterns us ing a pa n el 
of 7 a nt ibodies (see T able II). 
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DISCU SSION 
This study addresses three issues: (1 ) the specifici ty or re-
striction of antigens detected by murine antibodies against 
putative melanoma a nt ige ns; (2) the a nt igenic phenotype of 
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TABLE I. Evaluation of antigens in nevi and melanomas 
Normal nevocellular nevi 




a N = Number examined. 
b /3211 == {:J2-microglobulin. 
FIG 1. Photograph of patient's (LM) 
leg pointing to metastatic melanoma le-
sion s #1, #3, and #5- Demonstrated here 
is the variability in clin ical appearance. 
FIG 2. Photomicrograph of lesions 
#1, #3, and #5. Epithelioid melanoma 
cells predominate in les ion #1. Lesion #3 
is composed of mixed spindle and epi-
t h el ioid ce lls, and les ion #5 is composed 














suspected precursor lesions of melanoma; and (3) the hete ro-
ge neity of metastatic les ions. It has been suggested t hat (32-
micr oglobulin and HLA-DR as well as me lanoma-assoc iated 
a ntigens p97 a nd p250 are good markers for melanoma [8- 10]. 
We arrive at a s imilar conclusion, alt hough the 4 markers we 
have exam ined were distributed widely, a nd could be found on 
a small percentage of nevocytes from nevocellula r nev i. Ruiter 
et al [8] reported an absence of both (32-microglobulin and 
HLA-DR in 10 nevocellular nevi , in contrast to the present 
HLA -D R p97 p250 No expression of antigen found 
5 1 5 
0 0 0 
1 0 1 0 
1 0 1 
9 7 9 0 
findings. Furthermore Natali et a l (10] corroborated an absence 
of HLA-DR on nevocellu lar nevi but found 100% staining for 
f3rmicroglobu lin. These differences may be related to sampling, 
or to t he reagents and technology employed. The source of 
nevocellular nevi we have studied may also contribute to dif-
ferences between this study and those of Ruiter eta! and Natali 
et a!. All 22 nonmalignant specimens we studied were derived 
from patients who had had a melanoma. It is possible that 
pigment cells from patients with a prior melanoma are biolog-
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TABLE II. Five metaBtatic lesions evaluated for immunohistology 
Lesion Appearancca Pigmentb Cell Type' Architecture" p97' p250' f3,J.L' DR' SB' MT,' Ia' 
1 FB Inc Ep 
2 FB Inc Ep 
3 ·FB/BR Inc Ep/Sp 
4 FBr Inc PI 
5 B Pigm Sp/De 
"FB = flesh colored with black pigment speckled non uniformly 
FB r = fl esh colored with brown pigment speckled nonuniformly 







"Inc = incontinent pigment present, melanocytes without pigment 
P igm = melanocytes with pigment 
' Ep = epitheloid 
Sp =spindle 
De = dendritic 
P I = pleiomo rphic 
ically and antigenically distinct from pigment cells in grossly 
and histologically similar lesions of normal individuals without 
p rior hi story of melanoma. This hypothesis requires further 
exploration, but would afford an attractive explanation for the 
increased risk of seco nd and subsequent melanomas in patients 
with a prior history of melanoma. Alt hough t he number of 
lesions ·evaluated has been limited in a ll published series, t he 
observation t hat HLA-DR exp ression increases with t he spec-
trum of dysplas ia ranging to a maximum in t he overt malig-
nancy suggests that expression of DR a nt igens may be closely 
related to the biologic process of transformation [9,11 ]. In 
addition to HLA-DR, our work suggests t hat j32-microglobulin 
is a usefu l marker for dysplasia. In the patient with a h istory 
of one melanoma, both 82-microglobulin and HLA-DR may be 
useful markers for unstable pigment cell processes. 
We have also shown in one patient t hat dermatotrophic 
metastases that vary grossly and microscopically ex hibi t a 
rather uniform antigenic phenotype. The phenotype of meta-
static lesions located in different organ systems may differ a nd 
now require more systemic evaluat ion. Albino et a l have de-
scribed differences in microscopic morphology a nd cell surface 
antigens of 6 mela noma cell lines derived from 6 different 
metastases from 1 patient [4]. The varied morphology, pigmen -
tation, and su rface a ntigens of thei r results are not incompati-
ble with those reported here. There is clearly heterogeneity 
wit hin each individual lesion noted in ou r study. Cultured lines 
may se lect for one or a nother of t he cell types within eac h 
lesion depending on growth characteristics, and t he number of 
cells of one type or another which comprise the lesion. Balaban 
et al have shown karyotype homogeneity of 5 metastases and 
primary lesion from 1 patient indicati ng t he clonal nature of 
the neoplasm [12]. This would be consistent with our fi ndings. 
Morphology and biochemical composition may be markers t hat 
follow or predict ant igenic phenotype [9]. Predisposit ion to 
certain patterns of metastases would be important to identify 
at primary surgery. Invasive behavior, if correlated to pheno-
typic characteristics identified by ava ilable murine monoclonal 
antibodies would provide valuable new determina nts of behav-
ior a nd prognosis as well [13]. T hus, a lt hough lesion l/3 and #4 
express p97 , lesion if4 expresses t his a n tigen in 50-75% of 
melanoma cell s as compared to less t han 25% of cells in lesion 
i/3. T hese findings a re significant, as antigenic density and 
hete rogeneity of cells within a lesion may be important for t he 
use of monoclonal antibodies for imaging and therapy [14]. 
+4 +8 +8 
+3 +8 +7 
+1 +7 +6 
+6 +8 +3 
+3 +8 +4 
"N =nests 
L = lymphatic invasion present 




+8 + 7 
+8 ND 
• 1 + = 0- 25% melanoma cells lightly staining + 
2+ = 0- 25% melanoma cells heavily staining + 
3+ = 25-50% melanoma cells lightly staining + 
4+ = 25-50% melanoma cells heavily staining 
5+ = 50-75% melanoma cells lightly staining 
6+ = 50- 75% melanoma cells heavily staining 
7+ = 75-100% melanoma cells lightly staining 
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